BPC-157 Dosage Protocols in Research: Experimental Models and Dosing Parameters

BPC-157 (Body Protection Compound 157) has been studied across a wide range of experimental models using varied dosing regimens, routes of administration, and treatment durations. Understanding how dosage parameters have been applied in the published literature, and the rationale behind them, is essential context for designing reproducible BPC-157 research. This guide summarizes the dosing frameworks used in preclinical BPC-157 studies, organized by model type and experimental endpoint.

For research use only. Not intended for human or veterinary use. This article describes dosing parameters used in published preclinical research and does not constitute dosing advice.

BPC-157 Background: Why Dosing Frameworks Vary

BPC-157 is a stable pentadecapeptide (15 amino acids) derived from a protective protein found in gastric juice. It has no known specific receptor but has been proposed to act through multiple pathways: upregulation of growth factor expression (VEGF, EGF, FGF), modulation of the nitric oxide (NO) system, activation of FAK-paxillin signaling, and interaction with the dopaminergic and serotonergic systems in CNS studies. This multi-target profile, combined with BPC-157’s documented stability in acidic environments, has led to its use in diverse model types, each with different optimal dosing rationale.

For a full mechanistic overview, see our BPC-157 Research Guide.

Dosing Parameters in Published Preclinical Research

Dose Range Used in Rodent Models

The overwhelming majority of published BPC-157 research uses rat models. Dose ranges reported in the literature span a wide range, from very low doses in the nanogram/kg range to microgram/kg doses, with the most commonly reported effective dose range being 10–200 µg/kg across various endpoints. Key patterns from the literature:

• Sikiric et al. (wound healing, tendon repair, GI models): Most studies from the primary BPC-157 research group use 10 µg/kg as the standard dose in rodents, administered intraperitoneally (IP) or intragastrically (IG). This dose consistently produces significant effects across GI healing, tendon repair, and systemic inflammation models.
• Higher doses (100–200 µg/kg): Used in some models, particularly bone healing and CNS studies, where 10 µg/kg produces subthreshold effects. Dose-response relationships are not always monotonic; several BPC-157 studies report that mid-range doses (10 µg/kg) outperform both lower and higher doses, consistent with a biological optimum rather than a linear dose-response.
• Very low doses (ng/kg range): Some studies report significant effects at doses as low as 1–10 ng/kg, particularly in GI mucosal protection models, an observation that has been cited as evidence for BPC-157’s potency but which warrants independent replication.

Routes of Administration

BPC-157 has been administered via multiple routes in published studies, with route selection driven by the research model and endpoint:

Treatment Duration and Timing

Treatment duration in BPC-157 studies varies considerably by endpoint:

• Acute GI protection models: Single-dose or 1–3 day treatment; BPC-157 demonstrates cytoprotective effects against acute mucosal injury (NSAIDs, ethanol, stress ulcers) within hours of administration
• Wound and soft tissue healing: Typically 7–14 days of daily dosing; histological endpoints (collagen organization, fibroblast density, vascularity) are assessed at sacrifice
• Tendon/ligament repair: 14–30 day protocols; biomechanical testing (failure load, stiffness) and histology used as endpoints
• Bone healing: 4–8 week protocols; radiographic and histomorphometric endpoints
• CNS and behavioral studies: Variable, acute dosing for neurotransmitter effect studies; 2–4 week courses for behavioral paradigms (locomotion, anxiolysis, dopamine system effects)

Timing relative to injury is also a study design variable. Some models administer BPC-157 immediately at the time of injury (pre-emptive/concurrent), others begin treatment 24–48 hours post-injury (delayed), and some examine prophylactic pre-treatment. Results across these designs suggest BPC-157’s effects are not limited to acute administration, delayed treatment protocols also produce significant healing outcomes.

Model-Specific Dosing Summaries

Gastrointestinal Models

Sikiric et al. have published extensively on BPC-157 in GI models. Representative dosing parameters:

• NSAID-induced gastric lesion models: 10 µg/kg IP or IG; single dose given concurrently with ulcerogenic agent or within 30 minutes; significant lesion reduction vs. vehicle at 24-hour endpoint
• Ethanol-induced gastric mucosal injury: 10 µg/kg IP; single dose; mucosal protection documented histologically within 1 hour
• Stress ulcer (restraint + water immersion): 10 µg/kg IP; significant reduction in ulcer index; also effective orally (drinking water administration)
• Inflammatory bowel models (TNBS colitis): 10 µg/kg daily IP for 7 days; histological and biochemical inflammation markers reduced

Musculoskeletal and Tendon Repair Models

Tendon and muscle repair studies have used both systemic and local BPC-157 administration:

• Transected Achilles tendon (rat): 10 µg/kg/day IP or SC for 14–21 days; significantly improved tendon organization, collagen fiber alignment, and biomechanical properties vs. vehicle
• Local tendon injection: Single or repeated injections of BPC-157 directly at transection site; studies report comparable or superior outcomes to systemic dosing for biomechanical endpoints
• Muscle crush injury: 10 µg/kg IP daily for 14 days; improved muscle fiber regeneration and functional recovery
• Quadriceps/patellar tendon repair: 10 µg/kg with similar protocols; positive outcomes across multiple studies from the Sikiric group

CNS and Neurological Models

CNS studies have used varied doses depending on endpoint:

• Dopamine system (dopamine depletion, haloperidol-induced catalepsy): 10 µg/kg IP; acute and chronic administration; dopaminergic normalization documented in multiple paradigms
• Spinal cord injury models: 10–200 µg/kg; functional recovery (hindlimb locomotion scales) and histological endpoints; local epidural administration also studied
• Peripheral nerve crush: 10 µg/kg IP daily; functional recovery and nerve fiber regeneration measured at 4–8 weeks
• Traumatic brain injury: 10 µg/kg; administered within hours of injury; outcomes include neurological deficit scoring and histological markers of damage

Reconstitution for Research Use

BPC-157 is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water prior to research use.

• Add bacteriostatic water slowly along the inner vial wall; swirl gently to dissolve; do not shake
• Solution should be clear and colorless
• Typical research stock concentration: 500 µg/mL or 1 mg/mL; dilute further in sterile saline as needed for volume-matched dosing
• Refrigerate at 2–8°C after reconstitution; stable approximately 4 weeks; protect from light
• Do not freeze reconstituted solution; lyophilized powder may be stored at -20°C

See: What Is Bacteriostatic Water? and the BPC-157 Research Guide for full context.

References

• Sikiric, P., Seiwerth, S., Rucman, R., Turkovic, B., Rokotov, D. S., Brcic, L., … & Boban Blagaic, A. (2018). Focus on ulcerative colitis: Stable gastric pentadecapeptide BPC 157. Current Medicinal Chemistry, 19(1), 126–132.
• Sikiric, P., Seiwerth, S., Rucman, R., Drmic, D., Stupnisek, M., Kokot, A., … & Blagaic, A. B. (2016). Stress in gastrointestinal tract and stable gastric pentadecapeptide BPC 157. Current Neuropharmacology, 14(2), 138–151.
• Gwyer, D., Bhatt, D. L., & Rogers, N. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2), 153–159.
• Sikiric, P., Drmic, D., Sever, M., Klicek, R., Blagaic, A. B., Tvrdeic, A., … & Seiwerth, S. (2020). Fistula healing, anastomosis healing, and tumor necrosis. World Journal of Gastroenterology, 26(24), 3459–3481.

All content on this site is intended strictly for in vitro research and laboratory use. Products sold by Exceed Enhancement are not approved by the FDA and are not intended for human consumption, therapeutic use, or veterinary application.

Research-Grade BPC-157/TB500 Available

Exceed Enhancement offers research-grade BPC-157/TB500 for qualified research applications. View product specifications and ordering information →